BiotechTube

KW-0761 + Vorinostat

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cutaneous T-Cell Lymphoma

Conditions

Cutaneous T-Cell Lymphoma

Trial Timeline

Nov 1, 2012 → Feb 17, 2021

NCT ID
NCT01728805

About KW-0761 + Vorinostat

KW-0761 + Vorinostat is a phase 3 stage product being developed by Kyowa Kirin for Cutaneous T-Cell Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01728805. Target conditions include Cutaneous T-Cell Lymphoma.

What happened to similar drugs?

7 of 19 similar drugs in Cutaneous T-Cell Lymphoma were approved

Approved (7) Terminated (1) Active (11)
✅ONTAK (denileukin difitox, DAB389IL-2)EisaiApproved
✅ONTAKEisaiApproved
✅ONTAKEisaiApproved
✅MogamulizumabKyowa KirinApproved
✅Clopidogrel + TicagrelorAstraZenecaApproved
✅Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Normal Saline (Placebo)NovartisApproved
✅BexaroteneBausch HealthApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01728805Phase 3Completed

Competing Products

20 competing products in Cutaneous T-Cell Lymphoma

See all competitors
ProductCompanyStageHype Score
ONTAK (denileukin difitox, DAB389IL-2)EisaiApproved
43
ONTAKEisaiApproved
43
E7777 9 mcg/kgEisaiPhase 3
40
ONTAKEisaiApproved
43
MogamulizumabKyowa KirinApproved
47
Mogamulizumab + Brentuximab vedotinKyowa KirinPhase 1
36
MogamulizumabKyowa KirinPhase 2
39
EnzastaurinEli LillyPhase 2
35
Clopidogrel + TicagrelorAstraZenecaApproved
43
PembrolizumabMerckPhase 2
42
Comparator: vorinostatMerckPre-clinical
26
PembrolizumabMerckPhase 2
39
TR701 FAMerckPhase 2
35
MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 MonthsMerckPhase 2
35
PembrolizumabMerckPhase 2
42
Tulisokibart + PlaceboMerckPhase 2
39
Aspirin + Ipilimumab + PembrolizumabMerckPhase 2
35
Pembrolizumab + MogamulizumabMerckPhase 2
42
TR-701 FA + LinezolidMerckPhase 3
40
Pimasertib + DacarbazineMerckPhase 2
35